CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 39 enrolled
Drug / intervention
LY2484595 Reference Formulation (RF) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01450098
NCT01450098Phase 1Completed
CompareCT.gov

Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects

Eli Lilly and Company·interventional·Posted Oct 12, 2011·Updated Oct 3, 2018

In Brief

A Phase 1 clinical trial evaluating LY2484595 Reference Formulation (RF) and LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG) for Healthy Volunteers. Completed, enrolled 39 participants across 1 site.

Detailed Summary

The purpose of this study will be to evaluate the safety of a single dose of LY2484595 and to compare the amount of LY2484595 in the blood of healthy non-Asian subjects, Chinese subjects, and first-generation Japanese subjects after receiving a single oral dose of LY2484595 in a fasted state, after eating a low-fat meal, and after eating a high-fat meal.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 12, 2011
Enrollment StartOct 1, 2011
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.7 years ago

Interventions

LY2484595 Reference Formulation (RF)drug

Administered orally

LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)drug

Administered orally